EFSA: Aspartaam (E951) veilig bij normaal gebruik

De zoetstof aspartaam (E951) is veilig bij normaal gebruik, dat is de conclusie van de Europese voedselwarenautoriteit dinsdag na bestudering van de resultaten van wetenschappelijke onderzoek naar de stof.  De EFSA deed dit onderzoek op verzoek van de Europese Commissie in Brussel. Oorspronkelijk stond een nieuwe beoordeling over de veiligheid van aspartaam pas in 2020 op de rol, maar na signalen over mogelijke schadelijke gevolgen besloot de commissie de opdracht te vervroegen. Alleen personen met de stofwisselingsziekte PKU moeten aspartaam mijden.

aspartaamEFSA completes full risk assessment on aspartame and concludes it is safe at current levels of exposure
Aspartame and its breakdown products are safe for human consumption at current levels of exposure, EFSA concludes in its first full risk assessment of this sweetener. To carry out its risk assessment, EFSA has undertaken a rigorous review of all available scientific research on aspartame and its breakdown products, including both animal and human studies.

“This opinion represents one of the most comprehensive risk assessments of aspartame ever undertaken. It’s a step forward in strengthening consumer confidence in the scientific underpinning of the EU food safety system and the regulation of food additives”, said the Chair of EFSA’s Panel on Food Additives and Nutrient Sources Added to Foods (ANS Panel), Dr Alicja Mortensen.

Experts of ANS Panel have considered all available information and, following a detailed analysis, have concluded that the current Acceptable Daily Intake (ADI) of 40mg/kg bw/day is protective for the general population. However, in patients suffering from the medical condition phenylketonuria (PKU), the ADI is not applicable, as they require strict adherence to a diet low in phenylalanine (an amino acid found in proteins).

Following a thorough review of evidence provided both by animal and human studies, experts have ruled out a potential risk of aspartame causing damage to genes and inducing cancer. EFSA’s experts also concluded that aspartame does not harm the brain, the nervous system or affect behaviour or cognitive function in children or adults. With respect to pregnancy, the Panel noted that there was no risk to the developing fetus from exposure to phenylalanine derived from aspartame at the current ADI (with the exception of women suffering from PKU).

The opinion makes clear that the breakdown products of aspartame (phenylalanine, methanol and aspartic acid) are also naturally present in other foods (for instance, methanol is found in fruit and vegetables). The contribution of breakdown products of aspartame to the overall dietary exposure to these substances is low.

The opinion describes the criteria used to identify the studies relevant for the risk assessment and standards applied to evaluate the scientific evidence. EFSA’s experts examined all uncertainties related to the evaluation of aspartame. The opinion explains how these were addressed in the risk assessment to ensure that potential risks from aspartame were not underestimated.

The comprehensive review carried out by the ANS Panel was made possible following two public calls for data which made available a large body of scientific information, comprising both published and previously unpublished data and studies.

EFSA received over 200 comments during the public consultation on the draft opinion (that took place from 9 January 2013 to 15 February 2013) and all of these were considered. During the consultative phase EFSA also held a hearing with interested parties to discuss its draft opinion and the feedback received from the online public consultation. EFSA’s dialogue with stakeholders revealed that there were important aspects of the draft opinion that needed to be clarified in the final output.

EFSA is also publishing today the comments on the draft opinion received during the public consultation, its responses to the comments received and a statement on two recent publications, one from the US Environmental Protection Agency and the other Gift et al., that were brought to EFSA’s attention after the closure of the public consultation. Neither of these studies alters EFSA’s conclusion on aspartame.

Redactie Medicalfacts/ Janine Budding

Ik heb mij gespecialiseerd in interactief nieuws voor zorgverleners, zodat zorgverleners elke dag weer op de hoogte zijn van het nieuws wat voor hen relevant kan zijn. Zowel lekennieuws als nieuws specifiek voor zorgverleners en voorschrijvers. Social Media, Womens Health, Patient advocacy, patient empowerment, personalized medicine & Zorg 2.0 en het sociaal domein zijn voor mij speerpunten om extra aandacht aan te besteden.

Ik studeerde fysiotherapie en Health Care bedrijfskunde. Daarnaast ben ik geregistreerd Onafhankelijk cliëntondersteuner en mantelzorgmakelaar. Ik heb veel ervaring in diverse functies in de zorg, het sociaal domein en medische-, farmaceutische industrie, nationaal en internationaal. En heb brede medische kennis van de meeste specialismen in de zorg. En van de zorgwetten waaruit de zorg wordt geregeld en gefinancierd. Ik ga jaarlijks naar de meeste toonaangevende medisch congressen in Europa en Amerika om mijn kennis up-to-date te houden en bij te blijven op de laatste ontwikkelingen en innovaties. Momenteel ben doe ik een Master toegepaste psychologie.

De berichten van mij op deze weblog vormen geen afspiegeling van strategie, beleid of richting van een werkgever noch zijn het werkzaamheden van of voor een opdrachtgever of werkgever.

Recente artikelen